Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: A randomized, double-blind, placebo-controlled trial

Biological Psychiatry

Volumn 75, Issue 9, 2014, Pages 678-685

  Lin, Chieh Hsin ^a,b   Chen, Ping Kun ^a,b,c   Chang, Yue Cune ^e   Chuo, Liang Jen ^d   Chen, Yan Syun ^e,g   Tsai, Guochuan E ^f   Lane, Hsien Yuan ^a,g  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c LIN SHIN HOSPITAL   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e TAMKANG UNIVERSITY   (Taiwan)

^f HARBOR UCLA MEDICAL CENTER   (United States)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Alzheimer disease; clinical trial; D amino acids oxidase (DAAO) inhibitor; mild cognitive impairment; N methyl D aspartate; sodium benzoate

Indexed keywords

BENZOIC ACID; DEXTRO AMINO ACID OXIDASE; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE; ENZYME INHIBITOR; NOOTROPIC AGENT;

ABSENCE OF SIDE EFFECTS; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CLINICIAN INTERVIEW BASED IMPRESSION OF CHANGE PLUS CAREGIVER INPUT; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TAIWAN; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; COGNITION; D-AMINO-ACID OXIDASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NOOTROPIC AGENTS; SEVERITY OF ILLNESS INDEX; SODIUM BENZOATE; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84898904207     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.08.010     Document Type: Article

References (77)

1. D. Budd, L.C. Burns, Z. Guo, G. L'Italien, and P. Lapuerta Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: A Markov model simulation Clinicoecon Outcomes Res 3 2011 189 195
2. C. Loy, and L. Schneider Galantamine for Alzheimer's disease and mild cognitive impairment Cochrane Database Syst Rev 2006 CD001747
3. R. Raschetti, E. Albanese, N. Vanacore, and M. Maggini Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials PLoS Med 4 2007 e338
4. J. Birks, and L. Flicker Donepezil for mild cognitive impairment Cochrane Database Syst Rev 2006 CD006104
5. S.A. Lipton, and P.A. Rosenberg Excitatory amino acids as a final common pathway for neurologic disorders N Engl J Med 330 1994 613 622
6. L.V. Kalia, S.K. Kalia, and M.W. Salter NMDA receptors in clinical neurology: Excitatory times ahead Lancet Neurol 7 2008 742 755 (Pubitemid 351957932)
7. D.W. Choi Excitotoxic cell death J Neurobiol 23 1992 1261 1276
8. E. Scarpini, P. Scheltens, and H. Feldman Treatment of Alzheimer's disease: Current status and new perspectives Lancet Neurol 2 2003 539 547 (Pubitemid 36994993)
9. F. Gardoni, D. Mauceri, M. Malinverno, F. Polli, C. Costa, and A. Tozzi et al. Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression J Neurosci 29 2009 669 677
10. M. Pallàs, and A. Camins Molecular and biochemical features in Alzheimer disease Curr Pharm Des 12 2006 4389 4408 (Pubitemid 44718296)
11. B. Reisberg, R. Doody, B. Stöffler, F. Schmitt, S. Ferris, H.J. Möbius Memantine Study Group Memantine in moderate-to-severe Alzheimer disease N Engl J Med 348 2003 1333 1341
12. L.S. Schneider, K.S. Dagerman, J.P. Higgins, and R. McShane Lack of evidence for the efficacy of memantine in mild Alzheimer disease Arch Neurol 68 2011 991 998
13. W.J. Yoon, S.J. Won, B.R. Ryu, and B.J. Gwag Blockade of ionotropic glutamate receptors produces neuronal apoptosis through the Bax-cytochrome C-caspase pathway: The causative role of Ca2+ deficiency J Neurochem 85 2003 525 533 (Pubitemid 36438348)
14. L.M. Rowland, R.S. Astur, R.E. Jung, J.R. Bustillo, J. Lauriello, and R.A. Yeo Selective cognitive impairments associated with NMDA receptor blockade in humans Neuropsychopharmacology 30 2005 633 639 (Pubitemid 40271165)
15. M.P. Mattson Glutamate and neurotrophic factors in neuronal plasticity and disease Ann N Y Acad Sci 1144 2008 97 112
16. S. Tilleux, and E. Hermans Neuroinflammation and regulation of glial glutamate uptake in neurological disorders J Neurosci Res 85 2007 2059 2070 (Pubitemid 47172138)
17. J.W. Olney, and N.B. Farber Glutamate receptor dysfunction and schizophrenia Arch Gen Psychiatry 52 1995 998 1007
18. G. Segovia, A. Porras, A. Del Arco, and F. Mora Glutamatergic neurotransmission in aging: A critical perspective Mech Ageing Dev 122 2001 1 29 (Pubitemid 32332958)
19. A.W. Procter, J.M. Stirling, G.C. Stratmann, A.J. Cross, and D.M. Bowen Loss of glycine-dependent radioligand binding to the N-methyl-D-aspartate- phencyclidine receptor complex in patients with Alzheimer's disease Neurosci Lett 101 1989 62 66 (Pubitemid 19137647)
20. A.W. Procter, E.H. Wong, G.C. Stratmann, S.L. Lowe, and D.M. Bowen Reduced glycine stimulation of [3H]MK-801 binding in Alzheimer's disease J Neurochem 53 1989 698 704 (Pubitemid 19207360)
21. I.P. Chessell, A.W. Procter, P.T. Francis, and D.M. Bowen D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain Brain Res 565 1991 345 348
22. G.E. Tsai, W.E. Falk, J. Gunther, and J.T. Coyle Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment Am J Psychiatry 156 1999 467 469 (Pubitemid 29124172)
23. Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, et al. (in press): A randomized, double-blind, placebo-controlled add-on treatment of benzoate, a D-amino acid oxidase inhibitor, for schizophrenia JAMA Psychiatry
24. K. Fukui, and Y. Miyake Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase J Biol Chem 267 1992 18631 18638
25. M.A. Vanoni, A. Cosma, D. Mazzeo, A. Mattevi, F. Todone, and B. Curti Limited proteolysis and X-ray crystallography reveal the origin of substrate specificity and of the rate-limiting product release during oxidation of D-amino acids catalyzed by mammalian D-amino acid oxidase Biochemistry 36 1997 5624 5632 (Pubitemid 27214913)
26. J. Sasabe, Y. Miyoshi, M. Suzuki, M. Mita, R. Konno, and M. Matsuoka et al. D-amino acid oxidase controls motoneuron degeneration through D-serine Proc Natl Acad Sci U S A 109 2012 627 632
27. S. Esposito, A. Pristera, G. Maresca, S. Cavallaro, A. Felsani, and F. Florenzano et al. Contribution of serine racemase/d-serine pathway to neuronal apoptosis Aging Cell 11 2012 588 598
28. X. Huang, H. Kong, M. Tang, M. Lu, J.H. Ding, and G. Hu D-Serine regulates proliferation and neuronal differentiation of neural stem cells from postnatal mouse forebrain CNS Neurosci Ther 18 2012 4 13
29. S.M. Smith, J.M. Uslaner, and P.H. Hutson The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors Open Med Chem J 4 2010 3 9
30. Benzoic acid. Encyclopaedia Britannica Web site. Available at: http://global.britannica.com/EBchecked/topic/61357/benzoic-acid.
31. World Health Organization (2000): Concise International Chemical Assessment. Document No. 26. Geneva: World Health Organization. Available at: http://www.who.int/ipcs/publications/cicad/cicad26-rev-1.pdf. Accessed September 7, 2013
32. S.M. Smith, J.M. Uslaner, L. Yao, C.M. Mullins, N.O. Surles, and S.L. Huszar et al. The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine J Pharmacol Exp Ther 328 2009 921 930
33. T. Adage, A.C. Trillat, A. Quattropani, D. Perrin, L. Cavarec, and J. Shaw et al. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties Eur Neuropsychopharmacol 18 2008 200 214
34. K. Hashimoto, Y. Fujita, M. Horio, S. Kunitachi, M. Iyo, and D. Ferraris et al. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine Biol Psychiatry 65 2009 1103 1106
35. W.J. Zhao, Z.Y. Gao, H. Wei, H.Z. Nie, Q. Zhao, X.J. Zhou, and Y.X. Wang Spinal D-amino acid oxidase contributes to neuropathic pain in rats J Pharmacol Exp Ther 332 2010 248 254
36. N. Gong, Z.Y. Gao, Y.C. Wang, X.Y. Li, J.L. Huang, and K. Hashimoto et al. A series of D-amino acid oxidase inhibitors specifically prevents and reverses formalin-induced tonic pain in rats J Pharmacol Exp Ther 336 2011 282 293
37. H.K. Park, Y. Shishido, S. Ichise-Shishido, T. Kawazoe, K. Ono, and S. Iwana et al. Potential role for astroglial D-amino acid oxidase in extracellular D-serine metabolism and cytotoxicity J Biochem 139 2006 295 304
38. M.L. Batshaw, S.L. Hyman, J.T. Coyle, M.B. Robinson, I.A. Qureshi, E.D. Mellits, and S. Quaskey Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the ornithine transcarbamylase-deficient sparse-fur mouse Pediatr Res 23 1988 368 374
39. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944 (Pubitemid 14076461)
40. J.C. Morris The Clinical Dementia Rating (CDR): Current version and scoring rules Neurology 43 1993 2412 2414 (Pubitemid 23346995)
41. P.H. Lu, S.D. Edland, E. Teng, K. Tingus, R.C. Petersen, and J.L. Cummings Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 72 2009 2115 2121
42. M.F. Folstein, S.E. Folstein, and P.R. McHugh "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
43. W.G. Rosen, R.C. Mohs, and K.L. Davis A new rating scale for Alzheimer's disease Am J Psychiatry 141 1984 1356 1364
44. L.S. Schneider, J.T. Olin, R.S. Doody, C.M. Clark, J.C. Morris, and B. Reisberg et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11 suppl 2 1997 S22 S32
45. Wechsler D (1997): Wechsler Memory Scale, 3rd ed. San Antonio, TX: Psychological Association
46. T.A. Salthouse The processing-speed theory of adult age differences in cognition Psychol Rev 103 1996 403 428 (Pubitemid 126432206)
47. T. Habekost, A. Vogel, E. Rostrup, C. Bundesen, S. Kyllingsbaek, and E. Garde et al. Visual processing speed in old age Scand J Psychol 54 2013 89 94
48. G.A. Carlesimo, M. Mauri, A.M. Graceffa, L. Fadda, A. Loasses, and S. Lorusso et al. Memory performances in young, elderly, and very old healthy individuals versus patients with Alzheimer's disease: Evidence for discontinuity between normal and pathological aging J Clin Exp Neuropsychol 20 1998 14 29 (Pubitemid 28318055)
49. P. Chen, G. Ratcliff, S.H. Belle, J.A. Cauley, S.T. DeKosky, and M. Ganguli Patterns of cognitive decline in presymptomatic Alzheimer disease: A prospective community study Arch Gen Psychiatry 58 2001 853 858 (Pubitemid 32979303)
50. O. Lingjaerde, U.G. Ahlfors, P. Bech, S.J. Dencker, and K. Elgen The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr Scand Suppl 334 1987 1 100 (Pubitemid 17115352)
51. R. Rosenthal Essentials of Behavioral Research: Methods and Data Analysis 2nd ed. 1991 McGraw Hill New York
52. JB Cunningham, and E Gardner Power, effect and sample size using GPower: Practical issues for researchers and members of research ethics committees Evidence Based Midwifery 5 2007 132 136
53. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
54. Y.J. Huang, C.H. Lin, H.Y. Lane, and G.E. Tsai NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer's disease Curr Neuropharmacol 10 2012 272 285
55. P. Riederer, and S. Hoyer From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain J Neural Transm 113 2006 1671 1677 (Pubitemid 44657662)
56. K. Hashimoto, T. Fukushima, E. Shimizu, S. Okada, N. Komatsu, and N. Okamura et al. Possible role of D-serine in the pathophysiology of Alzheimer's disease Prog Neuropsychopharmacol Biol Psychiatry 28 2004 385 388 (Pubitemid 38130146)
57. J. Birks Cholinesterase inhibitors for Alzheimer's disease Cochrane Database Syst Rev 2006 CD005593
58. A. Burns, J. O'Brien, S. Auriacombe, C. Ballard, K. Broich, and R. Bullock et al. Clinical practice with anti-dementia drugs: A consensus statement from British Association for Psychopharmacology J Psychopharmacol 20 2006 732 755 (Pubitemid 44622739)
59. A. Fellgiebel [Alzheimer drugs for mild cognitive impairment] Neuropsychiatr 21 2007 230 233 (Pubitemid 350033424)
60. T.C. Russ, and J.R. Morling Cholinesterase inhibitors for mild cognitive impairment Cochrane Database Syst Rev 2012 9 CD009132
61. J.T. O'Brien, and A. Burns Clinical practice with anti-dementia drugs: A revised (second) consensus statement from the British Association for Psychopharmacology J Psychopharmacol 25 2011 997 1019
62. N. Farina, M.G. Isaac, A.R. Clark, J. Rusted, and N. Tabet Vitamin E for Alzheimer's dementia and mild cognitive impairment Cochrane Database Syst Rev 2012 11 CD002854
63. R. Malouf, and J. Grimley Evans Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people Cochrane Database Syst Rev 2008 CD004514
64. E. Sydenham, A.D. Dangour, and W.S. Lim Omega 3 fatty acid for the prevention of cognitive decline and dementia Cochrane Database Syst Rev 2012 6 CD005379
65. L. Flicker, and G. Grimley Evans Piracetam for dementia or cognitive impairment Cochrane Database Syst Rev 2001 CD001011
66. J. Birks, and J. Grimley Evans Ginkgo biloba for cognitive impairment and dementia Cochrane Database Syst Rev 2009 CD003120
67. J. Skinner, J.O. Carvalho, G.G. Potter, A. Thames, E. Zelinski, and P.K. Crane et al. The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): An expansion of the ADAS-Cog to improve responsiveness in MCI Brain Imaging Behav 6 2012 489 501
68. D.P. Salmon Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease Curr Top Behav Neurosci 10 2012 187 212
69. S.E. Price, G.J. Kinsella, B. Ong, E. Storey, E. Mullaly, and M. Phillips et al. Semantic verbal fluency strategies in amnestic mild cognitive impairment Neuropsychology 26 2012 490 497
70. C. Rios, L.F. Pascual, S. Santos, E. Lopez, T. Fernandez, and I. Navas et al. [Working memory and complex activities of everyday life in the initial stages of Alzheimer's disease] Revista de neurologia 33 2001 719 722 (Pubitemid 34076152)
71. A. Espinosa, M. Alegret, S. Valero, G. Vinyes-Junque, I. Hernandez, and A. Mauleon et al. A longitudinal follow-up of 550 mild cognitive impairment patients: Evidence for large conversion to dementia rates and detection of major risk factors involved J Alzheimers Dis 34 2013 769 780
72. M. Albert, D. Blacker, M.B. Moss, R. Tanzi, and J.J. McArdle Longitudinal change in cognitive performance among individuals with mild cognitive impairment Neuropsychology 21 2007 158 169 (Pubitemid 46631098)
73. R. Perneczky, C. Pohl, C. Sorg, J. Hartmann, K. Komossa, and P. Alexopoulos et al. Complex activities of daily living in mild cognitive impairment: Conceptual and diagnostic issues Age Ageing 35 2006 240 245
74. C.H. Lai, H.Y. Lane, and G.E. Tsai Clinical and cerebral volumetric effects of sodium benzoate, a D-amino acid oxidase inhibitor, in a drug-naive patient with major depression Biol Psychiatry 71 2012 e9 e10
75. R. Kapoor, K.S. Lim, A. Cheng, T. Garrick, and V. Kapoor Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1) Brain Res 1106 2006 205 210 (Pubitemid 44177639)
76. L. Verrall, M. Walker, N. Rawlings, I. Benzel, J.N. Kew, and P.J. Harrison et al. d-Amino acid oxidase and serine racemase in human brain: Normal distribution and altered expression in schizophrenia European J Neurosci 26 2007 1657 1669 (Pubitemid 47416520)
77. C.A. Strick, C. Li, L. Scott, B. Harvey, M. Hajos, and S.J. Steyn et al. Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain Neuropharmacology 61 2011 1001 1015